TY - JOUR
T1 - Personalized medicine tackles clinical resistance
T2 - Alectinib in ALK-positive non-small cell lung cancer progressing on first-generation ALK inhibitor
AU - Skoulidis, Ferdinandos
AU - Papadimitrakopoulou, Vassiliki A.
N1 - Publisher Copyright:
© 2016 American Association for Cancer Research.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Over the last 2 years, our therapeutic armamentarium against genomically defined subgroups of non-small cell lung cancer (NSCLC) has extended to patients with acquired resistance to front-line targeted therapy. Alectinib (Alecensa; Roche/Genentech), a second-generation, orally active, potent, and highly selective inhibitor of anaplastic lymphoma kinase (ALK), is indicated for patients with metastatic, ALK rearrangement-positive NSCLC whose disease has worsened after treatment with crizotinib or who became intolerant to the drug. Alectinib received orphan drug designation, breakthrough therapy designation, priority review status, and accelerated approval by the FDA.
AB - Over the last 2 years, our therapeutic armamentarium against genomically defined subgroups of non-small cell lung cancer (NSCLC) has extended to patients with acquired resistance to front-line targeted therapy. Alectinib (Alecensa; Roche/Genentech), a second-generation, orally active, potent, and highly selective inhibitor of anaplastic lymphoma kinase (ALK), is indicated for patients with metastatic, ALK rearrangement-positive NSCLC whose disease has worsened after treatment with crizotinib or who became intolerant to the drug. Alectinib received orphan drug designation, breakthrough therapy designation, priority review status, and accelerated approval by the FDA.
UR - http://www.scopus.com/inward/record.url?scp=84994580452&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994580452&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-16-1415
DO - 10.1158/1078-0432.CCR-16-1415
M3 - Article
C2 - 27609840
AN - SCOPUS:84994580452
SN - 1078-0432
VL - 22
SP - 5177
EP - 5182
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 21
ER -